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Introduction
============

Familial hypercholesterolemia (FH) is a common autosomal genetic disorder characterized by the triad of high low-density lipoprotein cholesterol (LDL-C), premature coronary artery disease (CAD), and tendon/cutaneous xanthoma^[@bib1]--[@bib3])^. Historically, the frequency of clinical homozygous FH (HoFH) has been estimated at 1 in a million, and for heterozygous FH (HeFH), 1 in 500 throughout the world^[@bib4])^. A recent report has also demonstrated a higher prevalence of HoFH and HeFH among the general population in Japan, estimated to be 1/171,167 and 1/208, respectively^[@bib5])^. It is estimated that there are more than 30 million patients with FH worldwide^[@bib6],\ [@bib7])^, including at least 300,000 HeFH patients in Japan^[@bib1])^. Patients with FH have excessive high LDL-C levels due to pathological genetic mutations and are at a significantly higher risk for cardiovascular diseases^[@bib8]--[@bib11])^. The Japanese Atherosclerosis Society (JAS) guidelines have reported that patients with HeFH develop CAD typically before reaching the age of 55 in men and of 65 in women^[@bib1])^, and a Japanese cohort study found that 70% of HeFH patients died of CAD^[@bib12])^. When FH patients are left untreated, the risk for developing CAD is 20 times greater than that of FH patients treated with cholesterol-lowering medications^[@bib13])^.

While early diagnosis and treatment for patients with FH are recommended to prevent CAD^[@bib1],\ [@bib14])^, most individuals with FH remain undiagnosed and untreated worldwide. The European Atherosclerosis Society (EAS) published a Consensus Statement in 2013 warning of the severe underdiagnosis of FH and its negative consequences^[@bib15])^. The vast majority of the diagnosed FH is categorized as HeFH, and Nordestgaard *et al.* estimated that less than 1% of HeFH patients were diagnosed in most countries^[@bib16])^. Among those diagnosed and treated, most were still unable to achieve the recommended LDL-C level targets, resulting in up to a 13-fold increased risk of CAD^[@bib16])^. It is speculated that Japan is no exception in this regard^[@bib16])^.

The 2012 and 2017 JAS guidelines and 2016 European Society of Cardiology (ESC)/EAS guidelines recommend a target of LDL-C \< 100 mg/dL in patients with FH without atherosclerotic cardiovascular disease (ASCVD)^[@bib1],\ [@bib2],\ [@bib15])^. Given that this recommendation is known to be difficult for FH patients to achieve in routine clinical practice, reduction of LDL-C by more than 50% is set as the secondary management target^[@bib1])^. The consensus is that lifestyle modification alone is generally not sufficient to achieve normalization of the lipid profile in FH patients; therefore, drug therapy is required, with statins recommended as the first line drug therapy^[@bib1],\ [@bib13])^. Previous clinical trials have shown that FH can be effectively treated with lipid-modifying therapies (LMTs) such as statins by reducing LDL-C levels and the risk of cardiovascular events^[@bib17],\ [@bib18])^. For patients in whom target LDL-C levels cannot be achieved using conventional statin therapy, more intensive therapies using other LMTs in combination with a statin are recommended^[@bib1])^.

Currently, the proportion of patients diagnosed with FH and treatment patterns for FH with LMTs in real-world clinical settings in Japan are unknown. Two previous studies have reported the prevalence of FH patients, including those treated with LMTs. Teramoto *et al.* (2005) investigated patients who received LMTs for more than 3 months in an outpatient setting in Japan and reported that 3.4% of these patients had received a diagnosis of FH^[@bib19])^. A more recent study reported that 0.6% of the statin-treated patients who had not achieved the recommended LDL-C targets had a diagnosis of FH^[@bib20])^. With the widespread use of statins and non-statin LMTs for LDL-C lowering in recent years, diagnosis of FH has become more challenging^[@bib20])^. Given the high risk of CAD and the excessive mortality risk among undiagnosed and undertreated FH patients, there is an urgent need to better understand the management of LDL-C levels for patients with FH in Japan.

Aim
===

The objective of the current study was to conduct a cross-sectional analysis to evaluate the epidemiology and real-world treatment patterns associated with LMTs, and to understand the current LDL-C levels among Japanese patients with diagnosed FH (FH-D) or suspected FH (FH-S).

Methods
=======

Database
--------

This was a retrospective observational study. The Medical Data Vision database, an electronic hospital-based administrative claims database, was used for this study. The database consists of inpatient and outpatient medical care data from hospitals across Japan. All hospitals in the database were for acute-care, with an average bed number of 350. The database contains anonymized patient-level information on demographics, clinical diagnoses, procedures, prescriptions, and laboratory tests.

Patient Selection
-----------------

Patients meeting the following inclusion criteria were selected for inclusion in the study (**[Fig. 1](#F1){ref-type="fig"}**): at least one recorded LDL-C value (measured by direct assay) in 2013, with the most recent LDL-C measurement in 2013 defined at the index date; evidence of either a diagnosis of FH and/or LDL-C ≥ 190 mg/dL during the 2-year period prior to the index date; and ≥ 20 years of age at the index date. In order to ensure that the complete medical history was covered and to determine prior LMT use, the included patients were also required to have ≥ 2 years of continuous representation in the database prior to the index date. Patients who did not have an LDL-C level of ≥ 190 mg/dL during the 2-year pre-index period were not included in the current analysis unless they had a diagnosis of FH.
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Given that FH is likely to be underdiagnosed in Japan, our study included the following primary and secondary populations: FH-D and FH-S patients, respectively. FH-D patients were defined as patients with at least one record of FH diagnosis entered by attending physicians during the 2-year period prior to the index date, and FH-S patients were defined as patients with at least one record of LDL-C level ≥ 190 mg/dL during the 2-year period prior to the index date.

Determination of Treatment Patterns
-----------------------------------

Based on the medication utilization status at the index date, patients were classified into the following three categories: "current LMT therapy" if a recorded LMT prescription was present on the index date or within 30 days prior to it (scenario A or B in **[Fig. 2](#F2){ref-type="fig"}**); "previous LMT therapy" if not currently treated but evidence of a prior recorded LMT during the 2-year pre-index period was present (scenario C in **[Fig. 2](#F2){ref-type="fig"}**); and "no LMT therapy" if no recorded LMT was present during the 2-year pre-index period.
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Current LMT therapy was further classified into three mutually exclusive categories: high-intensity statin therapy with or without other non-statin LMT; low-to-moderate-intensity statin with or without other non-statin LMT; and non-statin LMT only. High-intensity statin therapy was defined as atorvastatin ≥ 20 mg/day, rosuvastatin ≥ 10 mg/day, and pitavastatin 4 mg/day. All other statins and doses were defined as low-to-moderate-intensity statins in the present study. A third category was used to categorize non-statin LMT only without statin use. This classification scheme is different from the statin classification according to the 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines, which consider high-intensity statins to consist of atorvastatin ≥ 40 mg or rosuvastatin ≥ 20 mg^[@bib21])^. Non-statin LMTs included ezetimibe, niacin (nicotinic acid), and bile acid sequestrants (cholestyramine, colestimide).

Statistical Analyses
--------------------

All statistical analyses in this study were descriptive. Baseline characteristics, LMT utilization, and LDL-C levels were summarized using proportions and mean ± standard deviation (SD) as appropriate. All analyses were conducted with SAS software version 9.4.

Results
=======

Patient Characteristics
-----------------------

A total of 3,495 patients met the inclusion criteria. **[Table 1](#T1){ref-type="table"}** presents the baseline characteristics of all patients (*N* = 3,495), FH-D patients (*N* = 193), and FH-S patients (*N* = 3,339, including 37 overlapping with FH-D) at the index date. The average ages (SD) for all patients, FH-D patients, and FH-S patients were 63 (13.9), 67 (13.3), and 62 (13.9) years, respectively. The proportion of males for all patients, FH-D patients, and FH-S patients were 40.3%, 42.0%, and 40.1%, respectively. All diagnosed FH patients were classified as HeFH; none of the patients had HoFH.

###### Baseline characteristics of all patients, FH-D patients, and FH-S patients

  Characteristics                                       All patients   FH-D patients   FH-S patients
  ----------------------------------------------------- -------------- --------------- ---------------
  Age                                                                                  
      Mean (SD), years                                  62.7 (13.9)    67.2 (13.3)     62.4 (13.9)
  Sex                                                                                  
      Male, n (%)                                       1,409 (40.3)   81 (42.0)       1,340 (40.1)
  Living location                                                                      
      Metropolitan, n (%)                               2,843 (81.3)   161 (83.4)      2,710 (81.2)
  Comorbid conditions, n (%)                                                           
      CAD                                               584 (16.7)     82 (42.5)       515 (15.4)
      Ischemic stroke                                   42 (1.2)       2 (1.0)         41 (1.2)
      PAD                                               239 (6.8)      24 (12.4)       221 (6.6)
      Diabetes                                          1,001 (28.6)   74 (38.3)       937 (28.1)
      CKD Stage IV--V^[1](#tf1){ref-type="table-fn"}^   424 (12.1)     25 (13.0)       402 (12.0)
      Hypertension                                      1,934 (55.3)   133 (68.9)      1,818 (54.4%)

CAD: Coronary artery disease, PAD: Peripheral artery disease, CKD: Chronic kidney disease, FH: Familial hypercholesterolemia, FH-D: Diagnosed FH patients, FH-S: Suspected FH patients, SD: Standard deviation

CKD Stage IV--V: 30 \> eGFR or dialysis

Diagnosis of FH
---------------

Among all 3,495 patients, 5.5% (*N* = 193) had a diagnosis of FH. When focused on only the 1,708 and 103 patients who were currently receiving any statins and high-intensity statin, the rate of diagnosis of FH increased to 8.3% (*N* = 141) and 35.9% (*N* = 37), respectively.

LDL-C Management
----------------

**[Fig. 3](#F3){ref-type="fig"}** details the LDL-C levels at the index date for all patients, FH-D patients, and FH-S patients. The mean LDL-C levels for all patients, FH-D patients, and FH-S patients were 145.8 mg/dL, 119.2 mg/dL, and 147.6 mg/dL, which indicates a 16.5%, 32.1%, and 15.6% achievement rate of the recommended LDL-C levels of \< 100 mg/dL, respectively. Moreover, 42.7% (*N* = 35) of the FH-D patients with CAD, 24.3% (*N* = 27) of the FH-D patients without CAD, 23.9% (*N* = 123) of the FH-S patients with CAD, and 14.1% (*N* = 397) of the FH-S patients without CAD had achieved the LDL-C levels of \< 100 mg/dL. In the FH-D and FH-S patients with CAD, 13.4% (*N* = 11) and 3.7% (*N* = 19) had LDL-C levels of \< 70 mg/dL, respectively.
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The achieved LDL-C levels were also dependent on the current treatment type. In FH-D and FH-S patients treated with statins, approximately 37.0% (*N* = 57) and 24.0% (*N* = 447), respectively, achieved an LDL-C of \< 100 mg/dL, a greater proportion than that achieved by patients treated with non-statin LMT (21.1% for FH-D and 5.5% for FH-S) or not treated with LMT at all (5.0% for FH-D and 4.8% for FH-S).

Utilization of LMT
------------------

LMT utilization for all patients, FH-D patients, and FH-S patients is presented in **[Fig. 4](#F4){ref-type="fig"}**. For all patients, nearly half (44.5%) were currently not treated with any LMT, of which 35.3% received no LMT therapy over the 2-year period prior to the index date, and the remaining patients (9.2%) had previous LMT therapy prior to the index date. Among patients on current LMT therapy (55.5% of all patients), low-to-moderate-intensity statins were dominantly used (45.9%). In comparison, high-intensity statins and non-statin LMTs only were used by 2.9% and 6.6% of the patients, respectively.
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For FH-D patients, 81.9% were on current LMT therapy. The majority of the FH-D patients (53.9%) were on low-to-moderate-intensity statins, and 19.2% and 8.8% of the FH-D patients were on high-intensity statins and non-statin LMTs, respectively.

For the FH-S patients, 54.1% were on current LMT therapy, with the majority (45.3%) receiving low-to-moderate-intensity statins. Among the FH-S patients, 2.3% and 6.5% were on high-intensity statins and non-statin LMTs, respectively.

A detailed breakdown of the therapies according to the LDL-C range for all patients, FH-D patients, and FH-S patients is presented in the **[Supplementary Table](#T2){ref-type="table"}**. Among the FH-D and FH-S patients with LDL-C ≥ 100 mg/dL on any statin treatment, we found that 69.3% and 89.7% remained on monotherapy, respectively. Patients with FH-D were more likely to be treated with high-intensity statins (19.2%) compared with FH-S patients (2.3%).

###### Treatment patterns according to LDL-C range for all patients

  Treatment combinations                               All patients (*N* = 3,495)                                                                                                                                                     
  ---------------------------------------------------- ---------------------------- ------- -------- ---- -------- -------- ----- ------- -------- ----- ------- -------- ----- ------- -------- ----- ------- -------- ----- ------- --------
  Currently treated by at least one LMT                1,940                        55.5%   --       73   73.7%    --       398   83.1%   --       634   74.2%   --       435   58.7%   --       188   33.1%   --       212   28.2%   --
      Currently on High-Intensity Statin               103                          2.9%    100.0%   7    7.1%     100.0%   20    4.2%    100.0%   23    2.7%    100.0%   21    2.8%    100.0%   15    2.6%    100.0%   17    2.3%    100.0%
          Monotherapy                                  59                           1.7%    57.3%    2    2.0%     28.6%    13    2.7%    65.0%    10    1.2%    43.5%    12    1.6%    57.1%    11    1.9%    73.3%    11    1.5%    64.7%
          Plus Ezetimibe                               42                           1.2%    40.8%    5    7.1%     71.4%    7     1.5%    35.0%    12    1.4%    52.2%    9     1.2%    42.9%    4     0.7%    26.7%    5     0.7%    29.4%
          Plus Non-Ezetimibe                           2                            0.1%    1.9%     0    0.0%     0.0%     0     0.0%    0.0%     1     0.1%    4.3%     0     0.0%    0.0%     0     0.0%    0.0%     1     0.1%    5.9%
      Currently on Low- to Moderate-Intensity statin   1,605                        45.9%   100.0%   63   63.6%    100.0%   367   76.6%   100.0%   568   66.4%   100.0%   332   44.8%   100.0%   119   21.0%   100.0%   156   20.7%   100.0%
          Monotherapy                                  1,442                        41.3%   89.8%    48   76.2%    76.2%    328   68.5%   89.4%    527   61.6%   92.8%    295   39.8%   88.9%    104   18.3%   87.4%    140   18.6%   89.7%
          Plus Ezetimibe                               136                          3.9%    8.5%     13   20.6%    20.6%    33    6.9%    9.0%     33    3.9%    5.8%     32    4.3%    9.6%     10    1.8%    8.4%     15    2.0%    9.6%
          Plus Non-Ezetimibe                           27                           0.8%    1.7%     2    3.2%     3.2%     6     1.3%    1.6%     8     0.9%    1.4%     5     0.7%    1.5%     5     0.9%    4.2%     1     0.1%    0.6%
      Currently only on Non-statin LMT                 232                          6.6%    100.0%   3    3.0%     100.0%   11    2.3%    100.0%   43    5.0%    100.0%   82    11.1%   100.0%   54    9.5%    100.0%   39    5.2%    100.0%
          Any Ezetimibe                                198                          5.7%    85.3%    3    100.0%   100.0%   8     1.7%    72.7%    41    4.8%    95.3%    74    10.0%   90.2%    44    7.7%    81.5%    28    3.7%    71.8%
          Only non-Ezetimibe                           34                           1.0%    14.7%    0    0.0%     0.0%     3     0.6%    27.3%    2     0.2%    4.7%     8     1.1%    9.8%     10    1.8%    18.5%    11    1.5%    28.2%
  No current LMT                                       1,555                        44.5%   100.0%   26   26.3%    100.0%   81    16.9%   100.0%   221   25.8%   100.0%   306   41.3%   100.0%   380   66.9%   100.0%   541   71.8%   100.0%
      Previously Covered by LMT                        323                          9.2%    20.8%    11   11.1%    42.3%    36    7.5%    44.4%    78    9.1%    35.3%    57    7.7%    18.6%    62    10.9%   16.3%    79    10.5%   14.6%
      No Current or Prior LMT                          1,232                        35.3%   79.2%    15   15.2%    57.7%    45    9.4%    55.6%    143   16.7%   64.7%    249   33.6%   81.4%    318   56.0%   83.7%    462   61.4%   85.4%

FH: Familial hypercholesterolemia; FH-D: Diagnosed FH patients; FH-S: Suspected FH patients; LDL-C; Low-density lipoprotein cholesterol; LMT: Lipid-modifying therapy

###### Treatment patterns according to LDL-C range for FH-D patients

  Treatment combinations                               FH-D patients (*N* = 193)                                                                                                                                              
  ---------------------------------------------------- --------------------------- ------- -------- ---- ------- -------- ---- ------- -------- ---- ------- -------- ---- ------- -------- ---- ------- -------- --- ------- --------
  Currently treated by at least one LMT                158                         81.9%   --       16   88.9%   --       41   93.2%   --       57   82.6%   --       25   73.5%   --       12   66.7%   --       7   70.0%   --
      Currently on High-Intensity Statin               37                          19.2%   100.0%   5    27.8%   100.0%   7    15.9%   100.0%   9    13.0%   100.0%   10   29.4%   100.0%   3    16.7%   100.0%   3   30.0%   100.0%
          Monotherapy                                  16                          8.3%    43.2%    2    11.1%   40.0%    4    9.1%    57.1%    1    1.4%    11.1%    6    17.6%   60.0%    2    11.1%   66.7%    1   10.0%   33.3%
          Plus Ezetimibe                               21                          10.9%   56.8%    3    16.7%   60.0%    3    6.8%    42.9%    8    11.6%   88.9%    4    11.8%   40.0%    1    5.6%    33.3%    2   20.0%   66.7%
          Plus Non-Ezetimibe                           0                           0.0%    0.0%     0    0.0%    0.0%     0    0.0%    0.0%     0    0.0%    0.0%     0    0.0%    0.0%     0    0.0%    0.0%     0   0.0%    0.0%
      Currently on Low- to Moderate-Intensity statin   104                         53.9%   100.0%   11   61.1%   100.0%   30   68.2%   100.0%   39   56.5%   100.0%   13   38.2%   100.0%   7    38.9%   100.0%   4   40.0%   100.0%
          Monotherapy                                  83                          43.0%   79.8%    6    33.3%   54.5%    26   59.1%   86.7%    34   49.3%   87.2%    9    26.5%   69.2%    6    33.3%   85.7%    2   20.0%   50.0%
          Plus Ezetimibe                               15                          7.8%    14.4%    3    16.7%   27.3%    4    9.1%    13.3%    4    5.8%    10.3%    2    5.9%    15.4%    1    5.6%    14.3%    1   10.0%   25.0%
          Plus Non-Ezetimibe                           6                           3.1%    5.8%     2    11.1%   18.2%    0    0.0%    0.0%     1    1.4%    2.6%     2    5.9%    15.4%    0    0.0%    0.0%     1   10.0%   25.0%
      Currently only on Non-statin LMT                 17                          8.8%    100.0%   0    0.0%    --       4    9.1%    100.0%   9    13.0%   100.0%   2    5.9%    100.0%   2    11.1%   100.0%   0   0.0%    --
          Any Ezetimibe                                14                          7.3%    82.4%    0    0.0%    0.0%     2    4.5%    50.0%    8    11.6%   88.9%    2    5.9%    100.0%   2    11.1%   100.0%   0   0.0%    0.0%
          Only non-Ezetimibe                           3                           1.6%    17.6%    0    0.0%    0.0%     2    4.5%    50.0%    1    1.4%    11.1%    0    0.0%    0.0%     0    0.0%    0.0%     0   0.0%    0.0%
  No current LMT                                       35                          18.1%   100.0%   2    11.1%   100.0%   3    6.8%    100.0%   12   17.4%   100.0%   9    26.5%   100.0%   6    33.3%   100.0%   3   30.0%   100.0%
      Previously Covered by LMT                        15                          7.8%    42.9%    1    5.6%    50.0%    3    6.8%    100.0%   5    7.2%    41.7%    2    5.9%    22.2%    2    11.1%   33.3%    2   20.0%   66.7%
      No Current or Prior LMT                          20                          10.4%   57.1%    1    5.6%    50.0%    0    0.0%    0.0%     7    10.1%   58.3%    7    20.6%   77.8%    4    22.2%   66.7%    1   10.0%   33.3%

FH: Familial hypercholesterolemia; FH-D: Diagnosed FH patients; FH-S: Suspected FH patients; LDL-C; Low-density lipoprotein cholesterol; LMT: Lipid-modifying therapy

###### Treatment patterns according to LDL-C range for FH-S patients

  Treatment combinations                               FH-S patients (*N* = 3,339)                                                                                                                                                    
  ---------------------------------------------------- ----------------------------- ------- -------- ---- ------- -------- ----- ------- -------- ----- ------- -------- ----- ------- -------- ----- ------- -------- ----- ------- --------
  Currently treated by at least one LMT                1,806                         54.1%   --       59   71.1%   --       358   81.9%   --       581   73.3%   --       413   58.1%   --       183   32.6%   --       212   28.2%   --
      Currently on High-Intensity Statin               77                            2.3%    100.0%   3    3.6%    100.0%   14    3.2%    100.0%   15    1.9%    100.0%   14    2.0%    100.0%   14    2.5%    100.0%   17    2.3%    100.0%
          Monotherapy                                  47                            1.4%    61.0%    0    0.0%    0.0%     10    2.3%    71.4%    9     1.1%    60.0%    7     1.0%    50.0%    10    1.8%    71.4%    11    1.5%    64.7%
          Plus Ezetimibe                               28                            0.8%    36.4%    3    3.6%    100.0%   4     0.9%    28.6%    5     0.6%    33.3%    7     1.0%    50.0%    4     0.7%    28.6%    5     0.7%    29.4%
          Plus Non-Ezetimibe                           2                             0.1%    2.6%     0    0.0%    0.0%     0     0.0%    0.0%     1     0.1%    6.7%     0     0.0%    0.0%     0     0.0%    0.0%     1     0.1%    5.9%
      Currently on Low- to Moderate-Intensity statin   1,511                         45.3%   100.0%   53   63.9%   100.0%   337   77.1%   100.0%   531   67.0%   100.0%   319   44.9%   100.0%   115   20.5%   100.0%   156   20.7%   100.0%
          Monotherapy                                  1,367                         40.9%   90.5%    43   51.8%   81.1%    302   69.1%   89.6%    495   62.4%   93.2%    286   40.2%   89.7%    101   18.0%   87.8%    140   18.6%   89.7%
          Plus Ezetimibe                               122                           3.7%    8.1%     10   12.0%   18.9%    29    6.6%    8.6%     29    3.7%    5.5%     30    4.2%    9.4%     9     1.6%    7.8%     15    2.0%    9.6%
          Plus Non-Ezetimibe                           22                            0.7%    1.5%     0    0.0%    0.0%     6     1.4%    1.8%     7     0.9%    1.3%     3     0.4%    0.9%     5     0.9%    4.3%     1     0.1%    0.6%
      Currently only on Non-statin LMT                 218                           6.5%    100.0%   3    3.6%    100.0%   7     1.6%    100.0%   35    4.4%    100.0%   80    11.3%   100.0%   54    9.6%    100.0%   39    5.2%    100.0%
          Any Ezetimibe                                186                           5.6%    85.3%    3    3.6%    100.0%   6     1.4%    85.7%    33    4.2%    94.3%    72    10.1%   90.0%    44    7.8%    81.5%    28    3.7%    71.8%
          Only non-Ezetimibe                           32                            1.0%    14.7%    0    0.0%    0.0%     1     0.2%    14.3%    2     0.3%    5.7%     8     1.1%    10.0%    10    1.8%    18.5%    11    1.5%    28.2%
  No current LMT                                       1,533                         45.9%   100.0%   24   28.9%   100.0%   79    18.1%   100.0%   212   26.7%   100.0%   298   41.9%   100.0%   379   67.4%   100.0%   541   71.8%   100.0%
      Previously Covered by LMT                        313                           9.4%    20.4%    10   12.0%   41.7%    34    7.8%    43.0%    74    9.3%    34.9%    55    7.7%    18.5%    61    10.9%   16.1%    79    10.5%   14.6%
      No Current or Prior LMT                          1,220                         36.5%   79.6%    14   16.9%   58.3%    45    10.3%   57.0%    138   17.4%   65.1%    243   34.2%   81.5%    318   56.6%   83.9%    462   61.4%   85.4%

FH: Familial hypercholesterolemia; FH-D: Diagnosed FH patients; FH-S: Suspected FH patients; LDL-C; Low-density lipoprotein cholesterol; LMT: Lipid-modifying therapy

Discussion
==========

This study investigated real-world treatment patterns and clinical characteristics of LMTs among Japanese patients with FH-D or FH-S using a large hospital administrative claims database. To our knowledge, this is the first study that specifically focused on real-world clinical practice associated with FH in Japan.

FH is a common genetic cause of premature CAD due to lifelong elevated LDL-C levels. With the right diagnosis, patients with FH can be treated with LDL-C-lowering medication to attenuate the development of atherosclerosis and to prevent CAD^[@bib16])^. Current ESC/EAS guidelines recommend treatment to be initiated as early as possible to achieve the target LDL-C levels of \< 70 and \< 100 mg/dL in FH patients with and without ASCVD, respectively. This is also reflected in the newly revised 2017 JAS guidelines, which recommend target LDL-C levels of \< 70 and \< 100 mg/dL in FH patients with and without CAD, respectively^[@bib1],\ [@bib2],\ [@bib15])^.

The average LDL-C levels among FH patients in the current study (i.e., 145.8 mg/dL for all patients and 119.2 mg/dL for FH-D patients who were HeFH with or without LMT) were considerably lower than those previously reported in a study based on nationwide surveillance data from 1996--1998 (i.e., 248 mg/dL for HeFH patients without LMT)^[@bib22])^. The widespread use of statins and other LMTs for hypercholesterolemia as well as the rising FH awareness among physicians may have improved LDL-C management over the last 20 years. However, the findings of this study suggest that LDL-C levels are still not adequately managed in the majority of the Japanese patients with either FH-D or FH-S, as 67.9% (*N* = 131) and 84.4% (*N* = 2,819) of the FH-D and FH-S patients, respectively, had LDL-C levels of ≥ 100 mg/dL, which exceed the LDL-C target level recommended by the JAS guidelines. Although slightly higher achievements of LDL-C levels of \< 100 mg/dL were observed in the FH-D patients, LDL-C management was inadequate regardless of the presence of CAD. In addition, few FH-D and FH-S patients with CAD achieved the LDL-C target level of \< 70 mg/dL recommended by the newly revi sed 2017 JAS guidelines^[@bib2])^.

Inadequate treatment of FH has been reported worldwide^[@bib16],\ [@bib23])^, and the results of the present study revealed that Japan is no exception. Low-to-moderate-intensity statins were found to be the most commonly prescribed LMTs (45.9% of all patients), and 35.3% of all patients had no record of LMT prescriptions during the study period. The majority of the patients treated with statins remained on monotherapy even when their LDL-C levels were high. The JAS guidelines recommend drug therapy for patients with FH, using statins as first line followed by a combination therapy with non-statin LMT in further lines of therapy if monotherapy with statins was inadequate^[@bib13])^. While the JAS guidelines recommend aggressive statin therapy for FH patients, typically in the form of high doses of high-intensity statins, the majority of the patients in this study were found to receive low-to-moderate-intensity statins. Inadequate management of LDL-C levels may be partially related to lower proportions of patients receiving LMTs, especially high-intensity statins.

Low diagnostic rate of FH is another crucial factor for the lack of optimal therapy for high LDL-C levels. In this study, 5.5% of all patients had an existing diagnosis of FH. Our study also calculated the diagnosis rate among all patients currently treated with any statins and high-intensity statin to be only 8.3% and 35.9%, respectively. A report from Shiba *et al.* suggests a high likelihood of patients with LDL-C ≥ 190 mg/dL having FH^[@bib24])^. We defined FH-S patients as patients with LDL-C ≥ 190 mg/dL regardless of the status of the LDL-C-lowering therapy; therefore, we would expect our study population to have a rate of diagnosis of FH much higher than 5.5%. On the other hand, by applying a prevalence of HeFH in Japan of 1/208, as reported in a prior study^[@bib5])^, we could estimate that there are 372 patients with FH within our study population aged ≥ 20 years with 2-year baseline data (*N* = 77,415). We can then calculate that our study population has a 51.9% diagnosis rate (193 FH-D patients out of 372). However, this value needs to be interpreted with caution due to selection bias (e.g., exclusion of patients without LDL-C ≥ 190 mg/dL and larger acute-care hospital as a data source), making the diagnostic rate of 51.9% an upper limit to an overestimation of the true diagnosis rate. Nevertheless, given the aforementioned, we could conclude that the diagnostic rate of FH in facilities associated with acute-care hospitals is significantly higher than that previously reported for the general population, which likely represents higher prevalence and higher awareness of FH in this clinical setting.

The current study has also found a tendency for increased use of high-intensity statins within FH-D patients compared to all patients (19.2% of FH-D patients vs. 2.9% of all patients). There is also a higher rate of FH-D patients as LMT therapy intensifies, high-lighting the potential positive impact of an appropriate diagnosis on improving management of LDL-C levels among patients with FH. In fact, the average LDL-C levels reported in our study were considerably lower for FH-D patients (119.2 mg/dL) than for FH-S patients (147.6 mg/dL). This may reflect the trend of FH-D patients to seek treatment following a formal diagnosis and physicians to appropriately pursue more aggressive LDL-C-lowering therapy. It is important for Japanese clinicians to be acutely suspicious and proactively aware of the following diagnostic criteria for adult FH patients (meeting at least 2 of the following 3 items): 1) hyper-LDL cholesterolemia (LDL-C levels before treatment: ≥ 180 mg/dL); 2) tendon xanthoma (tendon xanthoma on the dorsal hands, elbows, and knees, or Achilles tendon thickening of ≥ 9 mm on radiography) or nodular xanthoma on the skin; and 3) family history of FH within the second-degree relatives or premature CAD. HoFH can also be diagnosed based on clinical features: serum total cholesterol of ≥ 600 mg/dL, cutaneous xanthoma, premature CAD during childhood, and parents\' family history of HeFH^[@bib13])^.

There are several limitations in this study. First, the use of a hospital database may represent selection bias that limits the generalizability of the results to the overall and FH populations in Japan. The data collected were limited to reflect clinical practice at larger acute-care hospital settings and patients who returned to the same hospital or clinic for continuous care with multiple LDL-C levels measured, limiting the generalizability of the results to continuously followed patients at larger hospitals. Secondly, it was not possible to follow patients who went to a different hospital or clinic, or to identify the same patient receiving care at more than one hospital in this database. The database also does not capture health services and prescriptions outside of the hospital. Third, patient demographics and clinical characteristics were limited to the information available during the 2-year pre-index period, which may have restricted the information used for clinical decision regarding the types of LMT prescribed or the diagnosis of FH itself. On the other hand, some of the patients who would have had pre-treated LDL-C ≥ 190 mg/dL prior to the 2-year pre-index period were not included in the current analysis. Fourth, the definition of FH-D and FH-S does not perfectly represent the diagnosis of FH used in clinical practice. We used LDL-C levels only to define FH-S populations without considering other factors such as family history, xanthoma, or possible secondary cause of hyperlipidemia. Furthermore, we could not exclude patients with a recorded diagnosis of FH in order to obtain insurance approval for certain prescriptions such atorvastatin 40 mg, which is only approved for patients with FH in Japan. Our study also used a relatively strict definition of "current therapy," defined by a recorded prescription on or within 30 days of the index date. In addition, the higher rate of females as well as younger patients included may be the reason for the lower intensity of LMT in the current analysis. Lastly, the current database did not allow an assessment of whether FH patients had lowered their LDL-C levels by more than 50% in this study. This may partly explain our findings showing that some of the treated patients remained above the LDL-C level of 100 mg/dL.

Conclusion
==========

The results of the present study suggest that treatment and management of LDL-C levels among patients with diagnosed and suspected FH in Japan remain suboptimal. The results also revealed a low rate of FH diagnosis in real-world clinical routine practice in Japan. There is an urgent need for more proactive diagnosis of FH and aggressive treatment targeting LDL-C levels \< 100 mg/dL for patients with FH in Japan.
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